alexa Nuclear Phosphoproteomics Features the Novel Smoking Ma
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Nuclear Phosphoproteomics Features the Novel Smoking Markers in Mouse Lung Tissue Following Subacute Phase Exposure to Tobacco Smoke

Kanako Niimori-Kita1*, Fumiko Nakamura1, Daikai Koizumi1and Daisuke Niimori2*
1Department of Pathology and Experimental Medicine, Kumamoto University, Honjo, Kumamoto, Japan
2Department of Dermatology and Plastic Surgery, Graduate School of Life Sciences, Kumamoto University, Honjo, Kumamoto, Japan
*Corresponding Author : Kanako Niimori-Kita
Department of Pathology and Experimental Medicine
Kumamoto University
1-1-1, Honjo, Kumamoto 860-8556, Japan
Tel: +81-96-373-5086
Fax: +81-96-373-5087
E-mail: [email protected]
  Daisuke Niimori
Department of Dermatology and Plastic Surgery
Kumamoto University, 1-1-1, Honjo
Kumamoto 860-8556, Japan
Tel: +81-96-373-5233
Fax: +81-96-373-5235
E-mail: [email protected]
Received February 19, 2016; Accepted February 27, 2016; Published March 05, 2016
Citation:Niimori-Kita K, Nakamura F, Koizumi D, Niimori D (2016) Nuclear Phosphoproteomics Features the Novel Smoking Markers in Mouse Lung Tissue Following Subacute Phase Exposure to Tobacco Smoke. J Bioanal Biomed 8:009-016. doi:10.4172/1948-593X.1000146
Copyright: © 2016 Niimori-Kita K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Smoking is a risk factor of lung diseases including chronic obstructive pulmonary disease (COPD) and lung cancer. However, the molecular mechanisms inducing these diseases remain to be completely uncovered. In order to elucidate them, it is necessary to identify the signaling pathway activated by tobacco smoking exposure. Especially, it is important to identify nuclear phosphoproteins induced by tobacco smoking exposure because the signaling pathways are modified by phosphoproteins. This time, to identify nuclear phosphoproteins as novel smoking markers, nuclear phosphoproteimics of mouse lung tissue following tobacco smoking exposure was examined. Tobacco smoking exposure against mice was examined using the nose-only, flow-past inhalation exposure chamber system for one month. Phosphopeptides eluted from nuclear proteins of the tobacco exposured mice lungs were identified by mass spectrometry. The result showed that 77 phosphoproteins were totally identified. Among them, the semiquantitative analysis using ProteoIQ proteomic software revealed that five phosphoproteins showed the different expression patterns between control and tobacco exposure groups. Furthermore, the classification by biological functions of the identified proteins revealed that these proteins were related to inflammation, regeneration, repair, proliferation, differentiation, morphological change and nicotine or stress response. Finally, we founded advanced glycosylation end product-specific receptor (RAGE) and serine/threonine-protein kinase SNF1-like kinase 2 (SIK2) as novel smoking markers.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version